In vivo small-animal PET/CT of EphB4 receptors using64Cu-labeled peptide

Journal of Nuclear Medicine

Volumn 52, Issue 2, 2011, Pages 241-248

  Xiong, Chiyi ^a   Huang, Miao ^a   Zhang, Rui ^a   Song, Shaoli ^a,b   Lu, Wei ^a   Flores II, Leo ^a   Gelovani, Juri ^a   Li, Chun ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

64Cu; EphB4 receptors; Peptide; Positron emission tomography

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID THREONYLASPARAGINYLTYROSYLLEUCYLARGINYLALANYLTRYPTOPHAN COPPER 64; COPPER 64; EPHRIN RECEPTOR B4; FLUORESCEIN ISOTHIOCYANATE; PEPTIDE; THREONYLASPARAGINYLTYROSYLLEUCYLARGINYLALANYLTRYPTOPHAN; THREONYLASPARAGINYLTYROSYLLEUCYLPHENYLALANYLSERYLPROLYLASPARAGINYLGLYCYLPROLYLIS OLEUCYLALANYLARGINYLALANYLTRYPTOPHAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; COLON CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONJUGATION; CONTROLLED STUDY; EVALUATION; FLUORESCENCE MICROSCOPY; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; ISOTOPE LABELING; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RECEPTOR BINDING; SURFACE PLASMON RESONANCE; TREATMENT RESPONSE;

ANIMALS; COLONIC NEOPLASMS; COPPER RADIOISOTOPES; DRUG STABILITY; FEMALE; HUMANS; ISOTOPE LABELING; MALE; MICE; MICE, NUDE; MICROSCOPY, FLUORESCENCE; MOLECULAR WEIGHT; PEPTIDES; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; PROTEIN ARRAY ANALYSIS; RADIOPHARMACEUTICALS; RECEPTOR, EPHB4; SURFACE PLASMON RESONANCE; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79851481921     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.081943     Document Type: Article

References (34)

1. 111In-DTPA-D-Phe1]-octreotide for detection of somatostatin receptor-positive tumors in rats. Life Sci. 1991;49:1593-1601.
2. Hammond PJ, Wade AF, Gwilliam ME, et al. Amino acid infusion blocks renal tubular uptake of an indium-labelled somatostatin analogue. Br J Cancer. 1993;67:1437-1439. (Pubitemid 23172893)
3. Haubner R, Decristoforo C. Radiolabelled RGD peptides and peptidomimetics for tumour targeting. Front Biosci. 2009;14:872-886.
4. Chen J, Cheng Z, Hoffman TJ, Jurisson SS, Quinn TP. Melanoma-targeting properties of 99mtechnetium-labeled cyclic a-melanocyte-stimulating hormone peptide analogues. Cancer Res. 2000;60:5649-5658.
5. Hargreaves R. Imaging substance P receptors (NK1) in the living human brain using positron emission tomography. J Clin Psychiatry. 2002;63:18-24. (Pubitemid 35435004)
6. Blower PJ, Puncher MRB, Kettle AG, et al. Iodine-123 salmon calcitonin, an imaging agent for calcitonin receptors: synthesis, biodistribution, metabolism and dosimetry in humans. Eur J Nucl Med. 1998;25:101-108.
7. 64Cu-labeled natriuretic peptide and PET. J Nucl Med. 2010;51:85-91.
8. Schottelius M, Wester H-J. Molecular imaging targeting peptide receptors. Methods. 2009;48:161-177.
9. Pasquale EB. Eph receptor signalling casts a wide net on cell behaviour. Nat Rev Mol Cell Biol. 2005;6:462-475. (Pubitemid 40780558)
10. Dodelet V, Pasquale E. Eph receptors and ephrin ligands: embryogenesis to tumorigenesis. Oncogene. 2000;19:5614-5619.
11. Noren NK, Lu M, Freeman AL, Koolpe M, Pasquale EB. Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth. Proc Natl Acad Sci USA. 2004;101:5583-5588.
12. Erber R, Eichelsbacher U, Powajbo V, et al. EphB4 controls blood vascular morphogenesis during postnatal angiogenesis. EMBO J. 2006;25:628-641. (Pubitemid 43237669)
13. Wang HU, Chen Z-F, Anderson DJ. Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell. 1998;93:741-753. (Pubitemid 28257581)
14. Xia G, Kumar SR, Stein JP, et al. EphB4 receptor tyrosine kinase is expressed in bladder cancer and provides signals for cell survival. Oncogene. 2006;25:769-780. (Pubitemid 43214703)
15. Davalos V, Dopeso H, Castano J, et al. EPHB4 and survival of colorectal cancer patients. Cancer Res. 2006;66:8943-8948. (Pubitemid 44521108)
16. Xia G, Kumar SR, Masood R, et al. EphB4 expression and biological significance in prostate cancer. Cancer Res. 2005;65:4623-4632. (Pubitemid 40740798)
17. Takai N, Miyazaki T, Fujisawa K, Nasu K, Miyakawa II. Expression of receptor tyrosine kinase EphB4 and its ligand ephrin-B2 is associated with malignant potential in endometrial cancer. Oncol Rep. 2001;8:567-573. (Pubitemid 33758456)
18. Kumar SR, Scehnet Jeffrey S, Ley Eric J, et al. Preferential induction of EphB4 over EphB2 and its implication in colorectal cancer progression. Cancer Res. 2009;69:3736-3745.
19. Stephenson S-A, Slomka S, Douglas E, Hewett P, Hardingham J. Receptor protein tyrosine kinase EphB4 is up-regulated in colon cancer [abstract]. BMC Mol Biol. 2001;2:15.
20. Kumar SR, Singh J, Xia G, et al. Receptor tyrosine kinase EphB4 is a survival factor in breast cancer. Am J Pathol. 2006;169:279-293.
21. Noren NK, Foos G, Hauser CA, Pasquale EB. The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl-Crk pathway. Nat Cell Biol. 2006;8:815-825. (Pubitemid 44151584)
22. Noren NK, Pasquale EB. Paradoxes of the EphB4 receptor in cancer. Cancer Res. 2007;67:3994-3997. (Pubitemid 46815041)
23. Koolpe M, Burgess R, Dail M, Pasquale EB. EphB receptor-binding peptides identified by phage display enable design of an antagonist with ephrin-like affinity. J Biol Chem. 2005;280:17301-17311. (Pubitemid 41389199)
24. Cooper MA. Optical biosensors in drug discovery. Nat Rev Drug Discov. 2002;1:515-528. (Pubitemid 37368826)
25. Bauer C, Bauder-Wuest U, Mier W, Haberkorn U, Eisenhut M. 131I-labeled peptides as caspase substrates for apoptosis imaging. J Nucl Med. 2005;46:1066-1074. (Pubitemid 43733525)
26. Berezov A, Zhang H-T, Greene MI, Murali R. Disabling ErbB receptors with rationally designed exocyclic mimetics of antibodies: structure-function Analysis. J Med Chem. 2001;44:2565-2574. (Pubitemid 32852146)
27. Chrencik JE, Brooun A, Recht MI, et al. Structure and thermodynamic characterization of the ephB4/ephrin-B2 antagonist peptide complex reveals the determinants for receptor specificity. Structure. 2006;14:321-330. (Pubitemid 43202021)
28. Liu W, Ahmad SA, Jung YD, et al. Coexpression of ephrin-Bs and their receptors in colon carcinoma. Cancer. 2002;94:934-939. (Pubitemid 34150847)
29. Huang X, Yamada Y, Kidoya H, et al. EphB4 overexpression in B16 melanoma cells affects arterial-venous patterning in tumor angiogenesis. Cancer Res. 2007;67:9800-9808. (Pubitemid 47621227)
30. Jain RK. Delivery of molecular and cellular medicine to solid tumors. J Control Release. 1998;53:49-67. (Pubitemid 28218689)
31. Hong SY, Oh JE, Lee K-H. Effect of D-amino acid substitution on the stability, the secondary structure, and the activity of membrane-active peptide. Biochem Pharmacol. 1999;58:1775-1780. (Pubitemid 29505418)
32. Shibata K, Suzawa T, Soga S, et al. Improvement of biological activity and proteolytic stability of peptides by coupling with a cyclic peptide. Bioorg Med Chem Lett. 2003;13:2583-2586. (Pubitemid 36830778)
33. 99mTc labeled to a peptide by 4 methods. J Nucl Med. 2001;42:1870-1877.
34. 111In-labeled DOTA-conjugated antibody fragments. Bioconjug Chem. 2001;12:264-270.